Efficacy and safety of Herbal Drink in mild to moderate Covid-19 patients: pilot study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211220001

Enrollment

100

Registered

2021-12-20

Start date

2021-12-21

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

confirmed RT-PCR for SAR-CoV-2 patients with mild to moderate symptoms mild-symptom covid-19 patients, moderate-symptom covid-19 patients, Herbal Drink, Favipiravir, viral clearance

Interventions

Experimental group will receive Herbal Drink 250 cc PO QID on day 1 to day 7 and Favipiravir group will receive Favipiravir treatment of 1800 mg PO BID on day 1, then 800 mg PO BID from day 2 to day 5

Experimental Dietary Supplement,Placebo Comparator Drug

Herbal Drink,Placebo

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. 20 (minimum) years of age 2. Diagnosis of COVID-19 infection confirmed by RT-PCR test for SAR-CoV-2 3. mild to moderate COVID-19 symptoms 4. No uncontrollable underlying disease 5. Onset of symptoms is within 5 days or positive RT-PCR for SAR-CoV-2 within 5 days 6. Signed informed consent provided by patient 7. Willing to stay at research site at least 10 days

Exclusion criteria

Exclusion criteria: 1. COVID19 positive based on Antigen test but PCR negative 2. Severe or critical clinical conditions (Glasgow coma scale less than 14) 3. Severe COVID-19 4. Patient who is on mechanical ventilator 5. Abnormal chest x-ray 6. Dyspnea or respiratory rate above 30 per minute 7. Hypoxia or oxygen saturation less than 96 percent 8. Underlying diseases including Diabetes mellitus, uncontrollable hypertension 9. Abnormal liver function test: ALT/AST increased 5 times higher than the upper limit of normal or with Child Pugh C 10. Renal failure or Creatinine clearance (Cockcroft-Gault Equation) less than 30 ml/min or having hemodialysis/peritoneal dialysis 11. Known allergy or hypersensitivity to Herbal Drink 12. Pregnant (female of childbearing age with positive urine pregnancy test) or Lactating female

Design outcomes

Primary

Measure	Time frame
Proportion of Viral clearance at day 7 day 7 Nasopharyngeal swab and RT-PCR for SAR-CoV-2	—

Secondary

Measure	Time frame
clinical improvement Every day from Day0 to Day7 or until discharge vital sign, symptoms, oxygen saturation	—

Countries

Thailand

Contacts

Public ContactPongsak Tangkana

Giving Mind Nirvana Soul Foundation

dls_pongsak@yahoo.com0816771467

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026